ArticleAngewandte Chemie (International ed. in English)2017
Smart Human-Serum-Albumin-As
Abstract read
In one paragraph
Article in Angewandte Chemie (International ed. in English), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 78 citations in OpenAlex.
- An all-in-one theranostic platform for enhanced TACE: self-developing embolization with dual-targeted arsenic trioxide delivery.Journal of nanobiotechnology · 2026Article
- Dual-site spatiotemporal and simultaneous inhibition on PIN1 via arsenic-retinoic albumin nanoparticles enables synergistic oncotherapy.Journal of nanobiotechnology · 2025Article
- High Spatiotemporal Near-Infrared II Fluorescence Lifetime Imaging for Quantitative Detection of Clinical Tumor Margins.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cancer Drug Targeting: Molecular Mechanism, Approaches, and Regulatory Framework.Current pharmaceutical design · 2025Review
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal transduction and targeted therapy · 2024Review
- Recent advance in phytonanomedicine and mineral nanomedicine delivery system of the treatment for acute myeloid leukemia.Journal of nanobiotechnology · 2023Review
- Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies.Journal of hematology & oncology · 2023Review
- Chitosan nanoparticles for sustained release of metformin and its derived synthetic biopolymer for bone regeneration.Frontiers in bioengineering and biotechnology · 2023Article
- Review
- Article
- Self-assembled Pt(II) metallacycles enable precise cancer combination chemotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy.Pharmaceutics · 2022Review
- Research progress of stimulus-responsive antibacterial materials for bone infection.Frontiers in bioengineering and biotechnology · 2022Review
- Effect of Fushengong Decoction on PTEN/PI3K/AKT/NF-κB Pathway in Rats With Chronic Renal Failure via Dual-Dimension Network Pharmacology Strategy.Frontiers in pharmacology · 2022Article
- Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects.Nature nanotechnology · 2021Article
- Arsenic trioxide induces macrophage autophagy and atheroprotection by regulating ROS-dependent TFEB nuclear translocation and AKT/mTOR pathway.Cell death & disease · 2021Article
- Nanovaccines for cancer immunotherapy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019Review
- An inorganic prodrug, tellurium nanowires with enhanced ROS generation and GSH depletion for selective cancer therapy.Chemical science · 2019Article
- Active targeting drug-gold nanorod hybrid nanoparticles for amplifying photoacoustic signal and enhancing anticancer efficacy.RSC advances · 2019Article
- Multifunctional Gold Nanoparticles Overcome MicroRNA Regulatory Network Mediated-Multidrug Resistant Leukemia.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Yongbo PengMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Life Sciences, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, 410082, China.ORCID 0000-0002-0173-9443
Zilong ZhaoMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Life Sciences, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, 410082, China.ORCID 0000-0002-9910-383X
Teng LiuMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Life Sciences, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, 410082, China.
Xiong LiDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, 410008, China.
Xiaoxiao HuMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Life Sciences, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, 410082, China.
Xiaoping WeiCenter for Clinical Molecular Medicine, Ministry of Education Key Laboratory of Child Development and Dis-orders, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China.
Xiaobing ZhangMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Life Sciences, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, 410082, China.ORCID 0000-0002-4010-0028
Weihong TanMolecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Life Sciences, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, 410082, China.ORCID 0000-0002-8066-1524
Hunan University · CNCentral South University · CNChildren's Hospital of Chongqing Medical University · CN
Funding
Development of molecular probes for biomedical applicationsR01GM079359 · NIGMS · UNIVERSITY OF FLORIDA · PI TAN, WEIHONG · 2007 to 2016
$2.3MMolecular Target for Liver Cancer Diagnosis and TherapyR01CA133086 · NCI · UNIVERSITY OF FLORIDA · PI LIU, CHEN · 2009 to 2013
$1.5MNCI NIH HHS R01 CA133086NIGMS NIH HHS R01 GM079359
Abstract
Arsenic trioxide (ATO, As
Indexed as
AnimalsAntineoplastic AgentsArsenic TrioxideCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorFolate Receptor 2HumansK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMiceNanoparticlesNeoplasms, ExperimentalSerum Albumin, HumanStructure-Activity RelationshipAntineoplastic AgentsArsenic TrioxideFolate Receptor 2FOLR2 protein, humanSerum Albumin, Humanarsenic trioxidechronic myeloid leukemiafolate receptor-βhuman serum albuminsmart nanodrugs
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.